Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma has received Japanese approval to market Betanis tablet (generic name:mirabegron) as a treatment of urinary frequency, urgency and urge urinary incontinence related to overactive bladder (OAB).
Subscribe to our email newsletter
Discovered and developed by Astellas, Betanis tablet improves urine collection function by activating ß3-adrenoceptor selectively on the bladder’s smooth muscles, relaxing bladder and improving OAB disorder.
Betanis tablet Phase 3 trial met objective and has showed efficacy in mirabegron treatment groups in mean change from baseline in number of micturitions per 24-hour (primary endpoint) compared to placebo.
Further, the company expects to file this product with the US Food and Drug Administration and European Medicines Agency in 2Q fiscal year 2011.